T-cell prolymphocytic leukemia (T-PLL) is an uncommon mature T-cell neoplasm characterized by the proliferation of abnormal lymphoid cells morphologically akin to prolymphocytes. 1 However, in some ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at ...

Because standard-of-care screening can identify early-stage cancers that MCED tests are less likely to detect, the incidence of malignant cancers that progressed from more indolent lesions may ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase 1/2 study. Patients received their CAR-T within 8 to 12 days of lymphodepletion.

KANEOHE (HawaiiNewsNow) - Honolulu Police are investigating a cell phone service outages that it says was caused by vandals. HPD issued an alert on social media at around 7 p.m. Saturday ...

Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor, developed as monotherapy or in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia (CLL)/small ...

Friday night was one to remember for Jasson Dominguez. Once dubbed the New York Yankees' top prospect, this is Dominguez's first full season, and we are now seeing why the Yankees have touted him ...

Devsisters have just released the Cookie Run Kingdom Pavlova Cookie as an Epic unit. He is a Ranged attacker who deals non-elemental damage from the Rear row. Therefore, players should focus on ...

"I'm thrilled that this new generation of CAR T cell therapy, created here at Penn, was highly effective in patients who have already tried everything available to treat their lymphoma," said ...

including in the disease subsets of large B-cell lymphoma (LBCL) and mantle cell lymphoma (MCL). While the common treatment-related toxicities of cytokine release syndrome (CRS) and immune ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers, more than ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with ...